Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Maria Cristina PirosaAnastasios StathisEmanuele ZuccaPublished in: Human vaccines & immunotherapeutics (2024)
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (FcγR) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis). In this product review, we will discuss its mechanism of action, safety profile and efficacy results from clinical trials that led to its approval in combination with lenalidomide for patients with R/R DLBCL ineligible for high-dose chemotherapy and autologous transplantation.
Keyphrases
- diffuse large b cell lymphoma
- high dose
- stem cell transplantation
- monoclonal antibody
- epstein barr virus
- low dose
- newly diagnosed
- natural killer cells
- clinical trial
- cell therapy
- end stage renal disease
- ejection fraction
- locally advanced
- cancer therapy
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- bone marrow
- acute lymphoblastic leukemia
- study protocol
- radiation therapy
- smoking cessation
- chemotherapy induced